Strategies to Combat Resistance to Anti-angiogenesis Therapies in Cancer: Current Status and Future Prospects

Area of Science:

• Oncology
• Cancer Biology
• Pharmacology

Background:

• Anti-angiogenic therapy targets tumor vasculature, offering a novel cancer treatment strategy.
• Efficacy is limited by mechanistic complexity, toxicity, resistance, and lack of predictive biomarkers.
• Resistance mechanisms include genetic alterations, alternative angiogenic pathways, and bone marrow-derived cell recruitment.

Purpose of the Study:

• To examine current challenges and strategies for overcoming resistance to anti-angiogenic therapy.
• To identify potential biomarkers for predicting treatment response and monitoring therapy.
• To explore combination approaches to enhance anti-angiogenic treatment efficacy.

Main Methods:

• Review of current literature on anti-angiogenic therapy resistance mechanisms.
• Analysis of biomarker-guided therapy for treatment prediction and monitoring (e.g., circulating endothelial cells, IL-8, VEGFR).
• Evaluation of multi-targeted therapies (VEGFR, PDGFR, FGFR, c-MET inhibitors) and combination strategies.

Main Results:

• Biomarkers like circulating endothelial cells, IL-8, and VEGFR expression may predict treatment response.
• Multi-targeted inhibition demonstrates greater efficacy than single-pathway blockade.
• Combination therapies, including with cancer vaccines, radiotherapy, chemotherapy, and nanotechnology, show positive outcomes.

Conclusions:

• Overcoming resistance requires a multi-faceted approach combining targeted therapies.
• Precision medicine strategies are essential for enhancing anti-angiogenic therapy effectiveness.
• Integrated treatment strategies are crucial for improving patient outcomes in cancer therapy.